Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses

Balwantray C. Chauhan; Raymond P. LeBlanc; Marcelo T. Nicolela; Paul E. Rafuse; David M. Andrews; Mohammad Humayun; James MacNeill; Andrew C. Orr; John H. Quigley; George A. Sapp; Christine A. MacDonald; Helen M. Sauveur; Sara L. Lavender; A. Gordon Balazsi; Oscar P. Kasner; Nabil E. Saheb; Alan J. Coffey; W. Edward Connolly; Marino J. Discepola; Conrad C. Kavalec; Susan K. Lindley; Mark Mullie; Pearl Alexander; Bonnie May; Gordon R. Douglas; Stephen M. Drance; Frederick S. Mikelberg; Jeffrey A. Blicker; Robin S. Cottle; Vincent Wong; Zarina Pardhan; Mark R. Lesk; Pearl Alexander; Yvonne M. Buys; John G. Flanagan; Graham E. Trope; Catherine M. Birt; Michael W. Easterbrook; William G. Macrae; Samuel N. Markowitz; Maureen Wolpert; Emad Eskander; Christine Macgillivray; Andrew Vassallo

doi:10.1016/S0008-4182(06)80025-6

Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses

Balwantray C. Chauhan, Raymond P. LeBlanc, Marcelo T. Nicolela, Paul E. Rafuse, David M. Andrews, Mohammad Humayun, James MacNeill, Andrew C. Orr, John H. Quigley, George A. Sapp, Christine A. MacDonald, Helen M. Sauveur, Sara L. Lavender, A. Gordon Balazsi, Oscar P. Kasner, Nabil E. Saheb, Alan J. Coffey, W. Edward Connolly, Marino J. Discepola, Conrad C. KavalecSusan K. Lindley, Mark Mullie, Pearl Alexander, Bonnie May, Gordon R. Douglas, Stephen M. Drance, Frederick S. Mikelberg, Jeffrey A. Blicker, Robin S. Cottle, Vincent Wong, Zarina Pardhan, Mark R. Lesk, Pearl Alexander, Yvonne M. Buys, John G. Flanagan, Graham E. Trope, Catherine M. Birt, Michael W. Easterbrook, William G. Macrae, Samuel N. Markowitz, Maureen Wolpert, Emad Eskander, Christine Macgillivray, Andrew Vassallo

Medicine

Medicine

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Background: The Canadian Glaucoma Study is a multicentred, prospective longitudinal study designed to study a variety of systemic risk factors for the progression of open-angle glaucoma under a standardised interventional protocol for intraocular pressure (IOP) control. Methods: Newly or previously diagnosed patients with early to moderate open-angle glaucoma were recruited consecutively from 5 hospital-based university departments. Baseline parameters, including an assessment of peripheral vasospasm, haematologic, coagulation, and immunopathologic variables were obtained. Newly diagnosed patients were targeted for a ≥30% reduction in IOP, whereas previously diagnosed patients entered the study at a physician-defined target IOP. After baseline examinations, patients were followed at 4-month intervals with standard automated perimetry, short-wavelength automated perimetry, and confocal scanning laser tomography, and at 28-32-month intervals with stereo disc photography. If the patient had visual field progression with standard automated perimetry, a further ≥20% reduction in IOP was mandated. A standardized IOP treatment protocol, ranging from topical monotherapy to filtration surgery, was implemented. Results: A total of 258 patients (130 men and 128 women, median age 65.0 years) were enrolled. Baseline median values for visual acuity, visual field mean deviation, untreated IOP, and refractive error were 0.10 logMAR, -4.04 dB, 25.0 mm Hg, and 0.00 D, respectively. Approximately 30% of the patients were hypertensive, 16% had cardiovascular disease, 9% thyroid disease, 9% diabetes, 14% migraine, and 19% were smokers. The median follow-up was 5.3 years, with 148 (57.0%) and 51 (19.8%) patients completing ≥5 and >7 years follow-up, respectively. The cumulative visual field progression rate at 2,4,6, and 8 years was 11.3%, 21.5%, 33.1%, and 43.5%, respectively. Interpretation: We describe the study design and baseline patient characteristics of the Canadian Glaucoma Study and present some preliminary results. This long and close follow-up of a large group of patients will reveal the importance of several systemic factors for the progression of glaucoma.

Original language	English
Pages (from-to)	566-575
Number of pages	10
Journal	Canadian Journal of Ophthalmology
Volume	41
Issue number	5
DOIs	https://doi.org/10.1016/S0008-4182(06)80025-6
Publication status	Published - Oct 2006

Bibliographical note

Funding Information:
Supported by the E.A. Baker Foundation of the Canadian National Institute for the Blind (1994–2005) and by unrestricted grants from Allergan Canada Inc. (2003–2005), Merck Frosst Canada (2003–2005), and Pfizer Canada Inc. (2003–2005).

ASJC Scopus Subject Areas

Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0008-4182(06)80025-6

Cite this

Chauhan, B. C., LeBlanc, R. P., Nicolela, M. T., Rafuse, P. E., Andrews, D. M., Humayun, M., MacNeill, J., Orr, A. C., Quigley, J. H., Sapp, G. A., MacDonald, C. A., Sauveur, H. M., Lavender, S. L., Balazsi, A. G., Kasner, O. P., Saheb, N. E., Coffey, A. J., Connolly, W. E., Discepola, M. J., ... Vassallo, A. (2006). Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Canadian Journal of Ophthalmology, 41(5), 566-575. https://doi.org/10.1016/S0008-4182(06)80025-6

Chauhan, BC , LeBlanc, RP , Nicolela, MT , Rafuse, PE, Andrews, DM, Humayun, M, MacNeill, J, Orr, AC, Quigley, JH, Sapp, GA, MacDonald, CA, Sauveur, HM, Lavender, SL, Balazsi, AG, Kasner, OP, Saheb, NE, Coffey, AJ, Connolly, WE, Discepola, MJ, Kavalec, CC, Lindley, SK, Mullie, M, Alexander, P, May, B, Douglas, GR, Drance, SM, Mikelberg, FS, Blicker, JA, Cottle, RS, Wong, V, Pardhan, Z, Lesk, MR, Alexander, P, Buys, YM, Flanagan, JG, Trope, GE, Birt, CM, Easterbrook, MW, Macrae, WG, Markowitz, SN, Wolpert, M, Eskander, E, Macgillivray, C & Vassallo, A 2006, 'Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses', Canadian Journal of Ophthalmology, vol. 41, no. 5, pp. 566-575. https://doi.org/10.1016/S0008-4182(06)80025-6

@article{bdc523ba8b664d2c8da7e90550d8d4ba,

title = "Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses",

abstract = "Background: The Canadian Glaucoma Study is a multicentred, prospective longitudinal study designed to study a variety of systemic risk factors for the progression of open-angle glaucoma under a standardised interventional protocol for intraocular pressure (IOP) control. Methods: Newly or previously diagnosed patients with early to moderate open-angle glaucoma were recruited consecutively from 5 hospital-based university departments. Baseline parameters, including an assessment of peripheral vasospasm, haematologic, coagulation, and immunopathologic variables were obtained. Newly diagnosed patients were targeted for a ≥30% reduction in IOP, whereas previously diagnosed patients entered the study at a physician-defined target IOP. After baseline examinations, patients were followed at 4-month intervals with standard automated perimetry, short-wavelength automated perimetry, and confocal scanning laser tomography, and at 28-32-month intervals with stereo disc photography. If the patient had visual field progression with standard automated perimetry, a further ≥20% reduction in IOP was mandated. A standardized IOP treatment protocol, ranging from topical monotherapy to filtration surgery, was implemented. Results: A total of 258 patients (130 men and 128 women, median age 65.0 years) were enrolled. Baseline median values for visual acuity, visual field mean deviation, untreated IOP, and refractive error were 0.10 logMAR, -4.04 dB, 25.0 mm Hg, and 0.00 D, respectively. Approximately 30% of the patients were hypertensive, 16% had cardiovascular disease, 9% thyroid disease, 9% diabetes, 14% migraine, and 19% were smokers. The median follow-up was 5.3 years, with 148 (57.0%) and 51 (19.8%) patients completing ≥5 and >7 years follow-up, respectively. The cumulative visual field progression rate at 2,4,6, and 8 years was 11.3%, 21.5%, 33.1%, and 43.5%, respectively. Interpretation: We describe the study design and baseline patient characteristics of the Canadian Glaucoma Study and present some preliminary results. This long and close follow-up of a large group of patients will reveal the importance of several systemic factors for the progression of glaucoma.",

author = "Chauhan, {Balwantray C.} and LeBlanc, {Raymond P.} and Nicolela, {Marcelo T.} and Rafuse, {Paul E.} and Andrews, {David M.} and Mohammad Humayun and James MacNeill and Orr, {Andrew C.} and Quigley, {John H.} and Sapp, {George A.} and MacDonald, {Christine A.} and Sauveur, {Helen M.} and Lavender, {Sara L.} and Balazsi, {A. Gordon} and Kasner, {Oscar P.} and Saheb, {Nabil E.} and Coffey, {Alan J.} and Connolly, {W. Edward} and Discepola, {Marino J.} and Kavalec, {Conrad C.} and Lindley, {Susan K.} and Mark Mullie and Pearl Alexander and Bonnie May and Douglas, {Gordon R.} and Drance, {Stephen M.} and Mikelberg, {Frederick S.} and Blicker, {Jeffrey A.} and Cottle, {Robin S.} and Vincent Wong and Zarina Pardhan and Lesk, {Mark R.} and Pearl Alexander and Buys, {Yvonne M.} and Flanagan, {John G.} and Trope, {Graham E.} and Birt, {Catherine M.} and Easterbrook, {Michael W.} and Macrae, {William G.} and Markowitz, {Samuel N.} and Maureen Wolpert and Emad Eskander and Christine Macgillivray and Andrew Vassallo",

note = "Funding Information: Supported by the E.A. Baker Foundation of the Canadian National Institute for the Blind (1994–2005) and by unrestricted grants from Allergan Canada Inc. (2003–2005), Merck Frosst Canada (2003–2005), and Pfizer Canada Inc. (2003–2005).",

year = "2006",

month = oct,

doi = "10.1016/S0008-4182(06)80025-6",

language = "English",

volume = "41",

pages = "566--575",

journal = "Canadian Journal of Ophthalmology",

issn = "0008-4182",

publisher = "Canadian Ophthalmological Society",

number = "5",

}

TY - JOUR

T1 - Canadian Glaucoma Study

T2 - 1. Study design, baseline characteristics, and preliminary analyses

AU - Chauhan, Balwantray C.

AU - LeBlanc, Raymond P.

AU - Nicolela, Marcelo T.

AU - Rafuse, Paul E.

AU - Andrews, David M.

AU - Humayun, Mohammad

AU - MacNeill, James

AU - Orr, Andrew C.

AU - Quigley, John H.

AU - Sapp, George A.

AU - MacDonald, Christine A.

AU - Sauveur, Helen M.

AU - Lavender, Sara L.

AU - Balazsi, A. Gordon

AU - Kasner, Oscar P.

AU - Saheb, Nabil E.

AU - Coffey, Alan J.

AU - Connolly, W. Edward

AU - Discepola, Marino J.

AU - Kavalec, Conrad C.

AU - Lindley, Susan K.

AU - Mullie, Mark

AU - Alexander, Pearl

AU - May, Bonnie

AU - Douglas, Gordon R.

AU - Drance, Stephen M.

AU - Mikelberg, Frederick S.

AU - Blicker, Jeffrey A.

AU - Cottle, Robin S.

AU - Wong, Vincent

AU - Pardhan, Zarina

AU - Lesk, Mark R.

AU - Alexander, Pearl

AU - Buys, Yvonne M.

AU - Flanagan, John G.

AU - Trope, Graham E.

AU - Birt, Catherine M.

AU - Easterbrook, Michael W.

AU - Macrae, William G.

AU - Markowitz, Samuel N.

AU - Wolpert, Maureen

AU - Eskander, Emad

AU - Macgillivray, Christine

AU - Vassallo, Andrew

N1 - Funding Information: Supported by the E.A. Baker Foundation of the Canadian National Institute for the Blind (1994–2005) and by unrestricted grants from Allergan Canada Inc. (2003–2005), Merck Frosst Canada (2003–2005), and Pfizer Canada Inc. (2003–2005).

PY - 2006/10

Y1 - 2006/10

N2 - Background: The Canadian Glaucoma Study is a multicentred, prospective longitudinal study designed to study a variety of systemic risk factors for the progression of open-angle glaucoma under a standardised interventional protocol for intraocular pressure (IOP) control. Methods: Newly or previously diagnosed patients with early to moderate open-angle glaucoma were recruited consecutively from 5 hospital-based university departments. Baseline parameters, including an assessment of peripheral vasospasm, haematologic, coagulation, and immunopathologic variables were obtained. Newly diagnosed patients were targeted for a ≥30% reduction in IOP, whereas previously diagnosed patients entered the study at a physician-defined target IOP. After baseline examinations, patients were followed at 4-month intervals with standard automated perimetry, short-wavelength automated perimetry, and confocal scanning laser tomography, and at 28-32-month intervals with stereo disc photography. If the patient had visual field progression with standard automated perimetry, a further ≥20% reduction in IOP was mandated. A standardized IOP treatment protocol, ranging from topical monotherapy to filtration surgery, was implemented. Results: A total of 258 patients (130 men and 128 women, median age 65.0 years) were enrolled. Baseline median values for visual acuity, visual field mean deviation, untreated IOP, and refractive error were 0.10 logMAR, -4.04 dB, 25.0 mm Hg, and 0.00 D, respectively. Approximately 30% of the patients were hypertensive, 16% had cardiovascular disease, 9% thyroid disease, 9% diabetes, 14% migraine, and 19% were smokers. The median follow-up was 5.3 years, with 148 (57.0%) and 51 (19.8%) patients completing ≥5 and >7 years follow-up, respectively. The cumulative visual field progression rate at 2,4,6, and 8 years was 11.3%, 21.5%, 33.1%, and 43.5%, respectively. Interpretation: We describe the study design and baseline patient characteristics of the Canadian Glaucoma Study and present some preliminary results. This long and close follow-up of a large group of patients will reveal the importance of several systemic factors for the progression of glaucoma.

AB - Background: The Canadian Glaucoma Study is a multicentred, prospective longitudinal study designed to study a variety of systemic risk factors for the progression of open-angle glaucoma under a standardised interventional protocol for intraocular pressure (IOP) control. Methods: Newly or previously diagnosed patients with early to moderate open-angle glaucoma were recruited consecutively from 5 hospital-based university departments. Baseline parameters, including an assessment of peripheral vasospasm, haematologic, coagulation, and immunopathologic variables were obtained. Newly diagnosed patients were targeted for a ≥30% reduction in IOP, whereas previously diagnosed patients entered the study at a physician-defined target IOP. After baseline examinations, patients were followed at 4-month intervals with standard automated perimetry, short-wavelength automated perimetry, and confocal scanning laser tomography, and at 28-32-month intervals with stereo disc photography. If the patient had visual field progression with standard automated perimetry, a further ≥20% reduction in IOP was mandated. A standardized IOP treatment protocol, ranging from topical monotherapy to filtration surgery, was implemented. Results: A total of 258 patients (130 men and 128 women, median age 65.0 years) were enrolled. Baseline median values for visual acuity, visual field mean deviation, untreated IOP, and refractive error were 0.10 logMAR, -4.04 dB, 25.0 mm Hg, and 0.00 D, respectively. Approximately 30% of the patients were hypertensive, 16% had cardiovascular disease, 9% thyroid disease, 9% diabetes, 14% migraine, and 19% were smokers. The median follow-up was 5.3 years, with 148 (57.0%) and 51 (19.8%) patients completing ≥5 and >7 years follow-up, respectively. The cumulative visual field progression rate at 2,4,6, and 8 years was 11.3%, 21.5%, 33.1%, and 43.5%, respectively. Interpretation: We describe the study design and baseline patient characteristics of the Canadian Glaucoma Study and present some preliminary results. This long and close follow-up of a large group of patients will reveal the importance of several systemic factors for the progression of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=33750403157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750403157&partnerID=8YFLogxK

U2 - 10.1016/S0008-4182(06)80025-6

DO - 10.1016/S0008-4182(06)80025-6

M3 - Article

AN - SCOPUS:33750403157

SN - 0008-4182

VL - 41

SP - 566

EP - 575

JO - Canadian Journal of Ophthalmology

JF - Canadian Journal of Ophthalmology

IS - 5

ER -

Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this